CAMBRIDGE, Mass.--(BUSINESS WIRE)--FogPharma ®, a biopharmaceutical company committed to transforming the lives of patients through a new precision medicine approach widely applicable to important and ...
Intensity Therapeutics (INTS), with a ~$13M market cap, closed up nearly 395% Thursday after publishing phase 1/2 results on its candidate for metastatic or refractory cancers, INT230-6. The asset ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback